Skip to main navigation

Skip to Content

Stock
Financials
- SEC Filings
- Financial Reports
News & Events
Corporate Governance
Our Company
IR Resources

Press Releases

Year

Genenta to appoint Richard Slansky as CFO and Anthony Marucci as Board member

May 03, 2021

Genenta Imaging Partnership with IAG Optimizes Phase I/IIa Study of Temferon™ in Glioblastoma

Feb 01, 2021

Genenta to take part in gene therapy panel and two virtual investor events in January 2021

Jan 05, 2021

Genenta to appoint Stephen Squinto, experienced biotech executive and investor, as Chairman

Nov 23, 2020

Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme

Nov 16, 2020

Genenta presents company’s pipeline and the preliminary clinical data from Phase I/II in patients affected with glioblastoma multiforme at the Advanced Therapies Congress & Expo 2020

Sep 30, 2020

Genenta to present preliminary Phase I/II clinical data on Temferon™ in glioblastoma multiforme at Chardan’s 4th Annual Genetic Medicines Conference

Sep 30, 2020

Genenta presents the company overview at the Access China Forum 2020

Jul 30, 2020

Genenta to present at the LifeSci Partners Summer Symposium

Jul 30, 2020

Genenta presents at ASGCT preliminary pre-clinical and clinical data from Temferon™ Phase 1/2 study in patients with glioblastoma multiforme

May 15, 2020

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Next page
Last page

Displaying 31 - 40 of 55

Investor Contact

RSS Feeds

Print

ITALY
Dibit – San Raffaele Hospital
Via Olgettina, 58
20132 Milano

UNITED STATES
LaunchLabs – Alexandria Center
430 East 29th Street
New York NY 10016

PARTNERS

genenta-img-san_raffaele

© 2023 Genenta Science. All rights reserved - - Terms and conditions - Privacy Policy